Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Cash & Current Investments (2016 - 2025)

Corcept Therapeutics' Cash & Current Investments history spans 10 years, with the latest figure at $372.2 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 2.92% year-over-year to $372.2 million; the TTM value through Dec 2025 reached $372.2 million, down 2.92%, while the annual FY2025 figure was $372.2 million, 2.92% down from the prior year.
  • Cash & Current Investments for Q4 2025 was $372.2 million at Corcept Therapeutics, down from $421.7 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $473.2 million in Q2 2024 and bottomed at $223.5 million in Q4 2021.
  • The 5-year median for Cash & Current Investments is $371.1 million (2022), against an average of $376.5 million.
  • The largest annual shift saw Cash & Current Investments crashed 49.28% in 2021 before it soared 93.11% in 2022.
  • A 5-year view of Cash & Current Investments shows it stood at $223.5 million in 2021, then skyrocketed by 93.11% to $431.7 million in 2022, then fell by 14.7% to $368.2 million in 2023, then rose by 4.1% to $383.3 million in 2024, then dropped by 2.92% to $372.2 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Cash & Current Investments are $372.2 million (Q4 2025), $421.7 million (Q3 2025), and $342.2 million (Q2 2025).